Theravance Biopharma (TBPH) Capital Expenditures (QoQ) (2013 - 2024)
Theravance Biopharma (TBPH) Capital Expenditures (QoQ) (2013 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,166.67% |
| Sep 30, 2024 | -58.33% |
| Jun 30, 2024 | -60.44% |
| Mar 31, 2024 | -86.56% |
| Dec 31, 2023 | 3,123.81% |
| Sep 30, 2023 | -97.54% |
| Jun 30, 2023 | -9.17% |
| Mar 31, 2023 | 252.63% |
| Dec 31, 2022 | 566.67% |
| Sep 30, 2022 | -150.44% |
| Jun 30, 2022 | -54.80% |
| Mar 31, 2022 | -43.69% |
| Dec 31, 2021 | -57.27% |
| Sep 30, 2021 | 566.03% |
| Jun 30, 2021 | -91.17% |
| Mar 31, 2021 | 42.04% |
| Dec 31, 2020 | -39.32% |
| Sep 30, 2020 | -13.43% |
| Jun 30, 2020 | 148.22% |
| Mar 31, 2020 | -26.78% |